Kanamycin injection (Kantrex)


  • Antibiotic


  • Aminoglycoside antibiotic


  • Serious infections (P. aeruginosa, Proteus species, E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, Staphylococcus species)

  • Bacterial neonatal sepsis

  • Bacterial septicemia

  • Serious bacterial infections of the CNS (meningitis)

  • Urinary tract, respiratory tract, skin, bone and soft tissue (including burns) infections

  • Gram-negative infections

  • Emperic therapy for unknown serious infections

  • Unlabeled use:

    • multi-drug regimen for Mycobacterium avium complex infections


  • Generally not indicated for long-term therapy due to nephrotoxocity and ototoxicity


  • Pregnancy category D

  • May cause nephrotoxicity, therefore closely monitor renal function, especially in elderly patients.

  • May cause ototoxicity, therefore monitor hearing

  • Monitor peak and trough serum concentrations

  • In patients with extensive burns, altered pharmacokinetics may alter serum concentrations.

  • May produce hypomagnesemia, especially if poor or restricted diet.

  • Aminoglycosides have neuromuscular blockade activity with a curare-like effect.  Monitor patient’s neuromuscular function, especially in patients with myasthenia gravis, parkinsonism or infant botulism.

  • Administer over 30-60 minute infusion

Adverse Reactions (Side Effects):

  • Renal: oliguria, proteinuria, increased creatinine and BUN

  • Miscellaneous: apnea

  • Pain at injection site

  • Granular casts

  • “Malabsorption syndrome” characterized by increase in fetal fat, decrease in serum carotene and fall in xylose absorption


  • Administered by IM or IV injection

  • Do not exceed 1.5 grams per day by any route

  • Adults:

    • 1.5mg/kg/day divided into 2-3 equal doses

  • Aerosol treatment:

    • 250mg 2-4 times a day, diluted with 3mL of normal saline

Back to Medical Corps Pharmacy Page